Journal ArticleOPEN ACCESS

OP0126 INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

  • Galloway J
  • Buch M
  • Yamaoka K
  • et al.
Annals of the Rheumatic Diseases (2021) 80 70-71
DOI: 10.1136/annrheumdis-2021-eular.1416
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The Janus kinase (JAK)-1 preferential inhibitor filgotinib (FIL) improved rheumatoid arthritis (RA) signs and symptoms in 3 phase (P)3 trials.1–3 Like other RA therapies, JAK inhibition is associated with increased infection rates.4

Cite

CITATION STYLE

APA

Galloway, J., Buch, M. H., Yamaoka, K., Leatherwood, C., Pechonkina, A., Tiamiyu, I., … Winthrop, K. (2021). OP0126 INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. Annals of the Rheumatic Diseases, 80, 70–71. https://doi.org/10.1136/annrheumdis-2021-eular.1416

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free